Chengdu Jinweike Biotechnology Co., Ltd

Based in Chengdu, China, and founded in 2017, Chengdu Jinweike Biotechnology Co. , Ltd operates as a biopharmaceutical company that focuses on gene therapy for hereditary diseases, cardiovascular and cerebrovascular diseases, and neurodegenerative diseases. It has established a 3,000 square AAV novel gene drugs R&D platform, including GMP AAV production facilities, GMP plasmid production facilities, quality control, and animal experiment platforms. The founder as well as the Chief Scientist Officer, Yuquan Wei, is a member of the Chinese Academy of Sciences, and former vice president of Sichuan University.

The founder as well as the CEO, Yang Yang, has published more than 30 SCI papers and applied for 4 patents. In January 2025, the company closed a venture funding. The company's services can be categorized into AAV production service for R&D, and preparation of clinical grade AAV. Gene Vector has 12 different AAV serotypes to choose from, and provides customers with purified AAV virus, and quality control including the titer, purity, and endotoxin test reports.

The company has established a technology platform with AAV capsid modification, gene expression cassette design, large gene delivery, and gene editing as its core. Its product pipeline is deployed in the fields of ophthalmic diseases, neuromuscular diseases, genetic metabolic diseases, etc. The company generates revenue by developing and providing AAV new drug candidates for wet macular degeneration. Gene Vector will ues the venture funding to accelerate the clinical transformation and commercialization of AAV gene therapy pipeline.